Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying
The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?
Feb 21, 2022 02:30 PM
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
ChangingBio Completes a CNY 140 million Series A Round of Funding
ChangingBio (Chinese: 昌进生物) completed a CNY 140 million Series A round of funding. Bits x Bites led this funding round, followed by Eight Roads Ventures, Sherpa Venture Capital, GL Ventures, Grand Flight Investment, and Country Garden Venture Capital.
Jun 23, 2022 04:05 PM
RNA Biotech Therorna Bags Over CNY 280 Mn in Series A Financing Round
Therorna, specialized in the development of cutting-edge circular RNA technology-based vaccines and therapies, will accelerate the development of a new broad-spectrum COVID-19 vaccine and other product pipelines with the fresh proceeds.
Jun 23, 2022 03:45 PM